The Academy of Pharmaceutical Sciences
'Promoting the pharmaceutical sciences'

Boehringer's BLA for idarucizumab gets FDA priority review.....           Dicerna gets FDA orphan drug status for DCR-PH1 to treat primary hyperoxaluria type 1.....           BMS scores positive EMA opinion for Opdivo in advanced melanoma patients.....           AstraZeneca sales retreat in its effort to achieve huge growth by 2023.....           Reckitt Benckiser makes out big time on the misery of U.S. flu sufferers.....           In an affront to Teva, Mylan hikes Perrigo offer past $31B.....           Daiichi Sankyo gets EMA recommendation on clot buster.....           Biogen sales, profit miss the mark as Tecfidera flags.....           Hours after receiving new bid, Perrigo tells Mylan to take a hike.....           Mylan introduces MyHep tablets in India to treat chronic hepatitis C.....           MedImmune enters into immuno-oncology clinical trial deal with Juno Therapeutics.....           Actavis introduces Avycaz in US to treat cIAI and cUTI.....           ThromboGenics begins evaluation of Jetrea to treat retinal vein occlusion.....           Axxess signs manufacturing, marketing and distribution deal with Tong.....           UPDATED: FDA gives Boehringer's Pradaxa antidote a boost with fast-track review.....           OWC, GC Group to develop new cannabinoid-based drugs.....           Triphase begins Phase I trial of marizomib-bevacizumab combination to treat glioblastoma.....           Eli Lilly can thank Novartis--and low expectations--for its Q1 earnings beat.....           Novartis unleashes M&A scouts as GSK deal starts to deliver on margins.....           Stellar Humira sales underscore AbbVie's need for replacement meds.....           FDA gives Boehringer's Pradaxa antidote a boost with fast-track review.....           J&J pulls contraceptives in Canada on potency worries.....           Watch out, Big Pharma: A Teva-Mylan combo would remake the industry Top 10.....           Novo Nordisk launches Saxenda injection in US for weight management.....           FDA accepts for filing Bayer's sBLA for Betaconnect to treat RRMS.....           Strategia begins Phase I/IIa trial of anti-cancer agent to treat advanced hematologic malignancies.....           CymaBay gets FDA orphan drug status for MBX-8025 to treat hypertriglyceridemia.....           CanTx gets FDA orphan drug designation for Cantrixil to treat ovarian cancer.....           Pfizer's lung cancer drug Xalkori gets FDA breakthrough therapy status.....           Deep discounts allow Remicade biosimilar to grab 50% of Norway's market.....           Teva wants Mylan wants Perrigo, and the pundits go mad with opinions.....           RB recalls 1.5M units of Mucinex on acetaminophen concerns.....           Gilead should buy Vertex, analyst suggests--and the time is now.....           Eyeing big niche in obesity, Novo rolls out Saxenda at $1,000 per month.....           Teva offers to acquire Mylan for $40.1bn.....           NIH-funded study identifies OTC compounds that may replace damaged cells.....           Astellas, Potenza to develop new immuno-oncology therapeutics.....           Elite introduces generic hydroxyzine tablets.....           Relmada begins pharmacokinetic trial for new oral formulations of buprenorphine.....           Concordia acquires Covis Pharma commercial assets for $1.2bn.....           Actavis gets FDA approval for BOTOX expanded label to treat upper limb spasticity in adults.....           The Medicines Company gets FDA approval for new formulation of Minocin for injection.....           Ready for a Teva-Mylan scrap? It's here. Teva finally launches its $40B takeover bid.....           Teva has to pay a record-setting $512M to settle pay-for-delay case. Who's next?.....           Belgium and the Netherlands see safety in numbers for drug price negotiations.....           Boosted by Opsumit, one-time target Actelion is ready to make its own deals.....           UPDATED: Hedge funder Kyle Bass' latest patent targets? Imbruvica and Pharmacyclics.....           Think the pharma M&A party will start winding down? Think again.....           Perrigo spurned Mylan's $29B offer, but would a bigger one do?.....           Daiichi Sankyo agrees to sell up to $3.6bn stake in Sun Pharma.....           TetraLogic, Merck enter oncology clinical trial collaboration.....           Lilly reports positive results from Phase III trial of ixekizumab to treat psoriatic arthritis.....           ChemoCentryx begins Phase Ib trial of CCX872 to treat pancreatic cancer.....           Oasmia's Paclical cancer drug gets Russian marketing approval.....           Which deal gets done: Teva's rumored Mylan bid or Mylan's Perrigo offer?.....           Allergan to cut loose 577 more workers in Irvine.....           Pfizer prevails in first court test of Zoloft birth-defect claims.....           GSK yanks all doses of quadrivalent flu jab for potency problems.....           Daiichi Sankyo cashing out after merging Ranbaxy with Sun.....           Gunning for a spot in the next-gen autoimmune market, Lilly med hits goals in latest trial.....           Oncolytics' Reolysin gets orphan drug designation for malignant gliomas treatment.....           MedDay reports positive MD1003 Phase III trial results in patients with progressive MS.....           RegeneRx JV retains Ora to conduct RGN-259/GBT201 clinical trials in US.....           FDA grants orphan drug status for AstraZeneca's selumetinib to treat uveal melanoma.....           RXi Pharma gets FDA orphan drug status for melanoma drug samcyprone.....           Merck submits sBLA to FDA for Keytruda to treat NSCLC.....           Mersana's fleximer immunoconjugate shows potent activity in low HER2-expressing tumor models.....           Oncolytics' Reolysin gets orphan drug designation for malignant gliomas treatment.....           MedDay reports positive MD1003 Phase III trial results in patients with progressive MS.....           RegeneRx JV retains Ora to conduct RGN-259/GBT201 clinical trials in US.....           Isarna starts first-in-human ISTH0036 Phase I trial to treat glaucoma.....           Sun Pharma, Technion to develop new class of oncology drugs.....           FDA approves Sandoz's Glatopa for multiple sclerosis treatment.....           Analyst: Vivus generic threats a positive for obesity market.....           Merck KGaA shareholders rewarded for hard work of turning company around.....           BMS' PD-1 drug Opdivo continues on stellar trajectory.....           Medimmune, Immunocore to evaluate melanoma immunotherapy combinations.....           Baxter submits NDA to Japanese authorities seeking approval for BAX 855 to treat hemophilia A.....           CiRA, Takeda to develop iPS cell applications.....           Bristol-Myers Squibb transfers Erbitux rights in North America to Lilly.....           Lexicon, Bristol-Myers select development candidate for neuropathic pain.....           Otsuka scrambles to persuade judge to block Abilify copycats.....           Pacira's Exparel marketing falls under Justice Department microscope.....           New drug partnerships in Cuba? Regeneron's chief will be on the spot.....           AbbVie moves closer to Japan's crowded hep C field with priority review nod.....           Careful, European drugmakers. Fitch says M&A may be a bit too heated.....           Sanofi expands PA vaccine facility to prepare for dengue launch.....           Bad news, Teva--Sandoz has an FDA nod for generic Copaxone. But when will it launch?.....           BMS, focused on immuno-oncology, turns Erbitux over to Eli Lilly.....           GSK closing Pittsburgh office, putting 275 jobs at risk.....           AstraZeneca's cancer drug tremelimumab obtains FDA orphan drug status.....           Abbvie's HCV treatment ombitasvir/paritaprevir/ritonavir gets priority review in Japan.....           Amgen gets FDA approval for heart failure drug Corlanor.....           Eyenovia, Senju sign license and development agreement for ophthalmic therapeutics.....           SELLAS, TrojanTec to develop new TR-1 anti-cancer antennapedia technology.....           Coherus, Baxter amend collaboration agreement for etanercept biosimilar.....           RSS NEWSFEED....
Welcome to
The Academy of
Pharmaceutical Sciences
The Academy of Pharmaceutical Sciences (APS) is the UK-based professional membership body for Pharmaceutical Scientists.

We represent individuals and organisations from around the globe, throughout their development, in the delivery of excellence in the Pharmaceutical Science sector.
Recent meetings

APS Freeze drying and alternative drying technologies for parenterals

28 January 2015 - Loughborough

Freeze drying - is there an alternative process technology to consider for your biopharmaceuticals?

A very successful one day meeting was held to look at the latest challenges and opportunities in the preservation of biopharmaceuticals. The meeting explored new developments in the established technology of freeze drying and discussed possible alternatives of spray drying, protein crystallisation and supercritical fluid drying of biopharmaceuticals.


Latest News
Conference Awards: 5th APS International PharmSci Conference
5th APS International PharmSci Conference: Nottingham 2015. . Conference Awards:. APS Award Lecture sponsored by AstraZeneca; Call for Nominations. The APS is pleased to announce our Call for Nominations for this years APS Award Lecture sponsored by AstraZeneca, to be delivered at APS PharmSci 2015 (September 7th- 9th) at the East Midlands Conference Centre, Nottingham.. The award will entail the following for the recipient:. To be presented at APS PharmSci 2015 with complimentary registration for the event on the day.. To deliver a 45 minute lecture within a conference plenary session. Presentation of a cheque to be donated to a charity of your choice. To be recognized as an award recipient on the APS website. Nominations Nomination should consist of a brief C.V. and a 1 page summary of contribution in fields of:. Scientific contribution: Work should be outstanding and ambassadorial in their area with an international reputation Broad scientific awareness Nominations must be made by member of the Academy. Selection Process The recipient of the award will be appointed by a Selection Committee comprising of:. Representatives of the Academy Board Representatives of the APS PharmSci 2015 Organizing Committee . GSK Emerging Scientist Award 2015; Call for Nominations. GlaxoSmithKline and the Academy of Pharmaceutical Sciences present the GSK Emerging Scientist Award and invite post-graduate and post-doctoral researchers to submit an application.. Prize The winner will receive a Commemorative Award, £1,000 in prize money and an invitation to present the GSK Emerging Scientist Award Lecture on their work at APS PharmSci 2015.. Entry Criteria Entrants are welcome from researchers from across the globe in academia, industry, public service or other scientific establishments. The individual applicant should have demonstrated, through published work, a significant innovation which has the potential for application within the pharmaceutical industry.. Applicants must be within 10 years of commencing their first research position on the closing date to be eligible. Time spent in undergraduate education is excluded. Clarification on eligibility can be sought by submitting a copy of your CV to the APS at Submission Criteria Applicants are requested to submit their CV and a synopsis of their research of not more than 1000 words, focussing on its importance to the pharmaceutical industry. Diagrams and images will account for 50 words. Any references used should be cited fully using the Harvard system.. Entries should be submitted via email to Alan Ramsay at including ‘Emerging Scientist Award 2015’ in the subject field. Your email application must include your full name and postal address, a contact telephone number, your email, and your institution or organisation’s name. Entries will be judged by an APS panel.. . Timings Nominations for both awards must be received by Friday 5th June 2015 and should be sent to:. Email: Or by post to:. The Organising Committee APS PharmSci 2014 Academy of Pharmaceutical Sciences Unit Q Troon Way Business Centre Humberston Lane Leicester LE4 9HA. . Tel: 0116 274 7351. Fax: 0116 274 7365. . APS Emerging Scientist Bright Ideas Award 2015; Call for Nominations. In conjunction with this year’s conference (7th - 9th September, East Midland’s Conference Centre, Nottingham) we are pleased to announce the APS Emerging Scientists’ Bright Idea Award.. Applications are invited from students, undergraduates, recent graduates and recent post-docs to submit an innovative Bright Idea related to the Pharmaceutical Sciences with the chance for an Award of £500 as a contribution to turn the best idea into reality.. In addition to the Award the winner will be provided with the support of an experienced APS Board member to help them with their idea.. Applicants will be invited to present no-more than 2 slides on their idea at a session of the conference on Monday 7th September. There will be a vote on the ideas presented and the winner will be announced later in the day.. In the first instance you are invited to submit no more than 2 paragraphs detailing your idea and how you would spend £500 to progress it. . Last year’s entries included:. Patch with feedback to control drug delivery. Means of purifying API from trace impurities. Improving the understanding of roller compaction. Pre-filled syringes to dose paediatrics. 3D printing of drug doses -. Entries clearly marked as ‘APS Bright Idea Competition’ should be Emailed to to arrive no later than Friday 31st July 2015..
The academy of Pharmaceutical Sciences announces nomination for their awards of Fellowship and Eminent Fellowship of the Academy for 2015
The Academy of Pharmaceutical Sciences is pleased to announce nominations for two highly recognised and prestigious awards within pharmaceutical science for their members: Fellowship and Eminent Fellowship of the Academy. Fellowship of the Academy (self-nomination). The fellowship of the Academy is a science driven award and is self-nominated by members of the APS. Individuals nominating can come from all sectors where pharmaceutical scientists work, which is reflected in the criteria for eligibility. . Eligibility requirements. The nominated person must:. Have a minimum of 8 post training years in the pharmaceutical sciences. Have a minimum of 15 peer reviewed publications and /orpatents, with at least 2/3 as first or corresponding/senior author. Or have contributed substantially to the development of a medicinal product(s) , diagnostic or device. Or have contributed substantially to the development of novel technologies. Or have contributed substantially to pharmaceutical science education/training as evidenced by peer recognition- invited lectures, conference leadership, etc. and involvement in mentorship. Application process. Nominations are required to submit a CV and a one page summary detailing their contributions made using the above guidance.. Nominations must be sent to and received by the April 30th 2015. These will then be reviewed by the APS Board and applicants will be notified of the result by June 2015.. . Eminent Fellowship of the Academy (nominated by an APS member). This is an award recognising science and experience at international level with emphasis on advocacy and leadership and nominations of deserving individuals are made by APS members with two letters of support. Nomination can be from all sectors where pharmaceutical scientists work, which is reflected in the criteria for eligibility. . Eligibility requirements. The nominated person must:. Have a minimum of 10 years post qualification of involvement in the pharmaceutical sciences. Have made a significant contribution to multiple publications and /or patents. Be in a clear leadership role. Be recognised internationally for their achievements . Application process. The Nomination will be from an APS member with 2 letters of support (also from APS members). Nominations will require a two page CV and a one page career summary detailing the contributions made highlighting the criteria above. The individual being nominated would typically not be aware of their nomination.. Nominations must be sent to and received by April 30th 2015. The APS board will appoint a review panel (3) composed of Board and Advisory Board members and individuals making the nomination will be notified of the result by June 2015 for subsequent onward notification to the individual being nominated.. Past members who have won the Eminent Fellowship of the Academy can be seen on the APS website Please contact or telephone 0116 274 7531.
5th International APS PharmSci Conference 2015
7th - 9th September 2015, East Midlands Conference Centre, Nottingham. ONLINE REGISTRATION NOW OPEN The Academy of Pharmaceutical Scientist is pleased to announce that registration for the 5th International APS PharmSci Conference 2015 is now open! . The APS PharmSci 2015 Conference will showcase the best of pharmaceutical science from the UK and around the world bringing together academic and industrial institutions, providing state of the art technologies and a platform for the development of new pharmaceutical talent. The intention is to work with related partner organisations such as, JPAG, UK&ICRS, and the RPS together with the Academy's Focus Groups to deliver a high quality science programme.. For more information visit: . CALL FOR PAPERS The abstract submission process is now open. For more information on submitting an abstract, please visit us online here: The deadline for receipt of submissions is Friday, 1st May 2015. . . EXHIBITION OPPORTUNITIES Exhibition space for one of the country's largest gatherings of industrial scientists, academics, management and technicians involved in the "Science of Medicines" can now be reserved online using our interactive floorplan. . If you are interested in exhibiting please visit or contact Alan Ramsay on T: 0116 274 7351 for details or to reserve your space.. PLEASE NOTE EXHIBITION SPACES ARE LIMITED, SO DON'T DELAY AND BOOK YOUR STAND TODAY.. . SPONSORSHIP OPPORTUNITIES PharmSci 2015 provides your organisation with an ideal opportunity to increase it profile through a wide range of sponsorship opportunities. . For further details please contact Alan Ramsay on T: 0116 274 7351. .
APS Parkinson's Disease: From Patient to Product
Venue: GSK, Ware Tuesday 19th May 2015. Parkinson’s Disease affects one in 500 people, with an estimated prevalence of 127,000 people in the UK with the condition. The use of medicines is a mainstay in treatment and can lead to an improvement in symptoms and movement. However, as the disease progresses, this presents challenges to patients, carers and prescribers in terms of what to prescribe and how it is administered. These challenges require science and clinical practice to come together to develop solutions to optimise treatment management for patients. This one-day meeting organised by the Age-Related Medicines Focus Group, will showcase the latest research in science and clinical practice pertaining to Parkinson’s Disease, present the perspectives of patients, and highlight regulatory perspectives in drug development.. The APS is grateful to GSK for their contribution to this event. As part of their 300th year celebrations, GSK are hosting a number of scientific events including this one.. For more details on the programme, fee's and to register, please visit us online here:. .
Follow us
Upcoming Events
APS Board Meeting
28 - 29 April 2015
APS Parkinson's Disease: From Patient to Product
19 May 2015
APS Inhaled Product Development Workshop
11 - 12 June 2015
APS 5th International PharmSci Conference 2015
7 - 9 September 2015
APS Joint Meeting with BSNM
10 September 2015
Job Vacancies
View all Vacancies
Advertise your job vacancies
Sponsored By
Join Us

Join the academy and get discounts on events, post-nominals, latest news and more.


The Academy of Pharmaceutical Sciences
Unit Q, Troon Way Business Centre
Humberstone Lane, Leicester, LE4 9HA
Tel: 0116 274 7351
Fax: 0116 274 7365

Terms of use:
The material included on this site is provided for information purposes only, and we make no representations or warranties as to its accuracy. Before relying on this material, you should take care to verify its accuracy, taking professional advice as appropriate.